New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2013
16:32 EDTALKS, TXT, EOPN, BAC, ACUR, CRUS, ENDP, AAPLOn The Fly: Closing Wrap
Stocks on Wall Street were sharply lower as the S&P and Nasdaq gave back all of yesterday's gains. The Dow returned almost all of yesterday's advance, logging its third consecutive triple-digit move. ECONOMIC EVENTS: The Federal Reserve's Beige Book, released this afternoon, said that economic activity expanded at a moderate pace, which was in-line with expectations. In Europe, Germany's top central banker said it may take Europe a decade to recover from its debt crisis and ratings agency Egan Jones reportedly cut its rating on Germany to A from A+. COMPANY NEWS: Apple's (AAPL) shares fell below $400 during the session and closed down $23.44, or 5.5%, at $402.80. One of the company's suppliers, Cirrus Logic (CRUS), estimated that revenue for its current quarter would be significantly below expectations, reinforcing expectations from some analysts that second quarter iPhone shipments will be much lower than in the first quarter. Cirrus shares lost $3.36, or 15.69%, to $18.05 following its warning and a number of other suppliers with exposure to Apple's supply chain fell also... Bank of America (BAC) reported headline earnings that missed consensus, though its revenue topped expectations. The bank also announced it has agreed to a $500M settlement in principle that would dismiss more suits brought against its Countrywide unit related to residential mortgage-backed securities. BofA was the Dow's worst performer following its quarterly report, falling 58c, or 4.72%, to $11.70. MAJOR MOVERS: Among notable gainers were shares of Acura Pharma (ACUR), up 73c, or 33.95%, to $2.88, and Endo Health (ENDP), up $1.10, or 3.16%, to $35.96 after the FDA announced it will not approve generic versions of non-tamper-resistant OxyContin. Also higher was Alkermes (ALKS), up $4.12, or 16.09%, to $29.72 after reporting preliminary results from a study of a drug candidate for major depressive disorder. Among the noteworthy losers was E2open (EOPN), down $4.49, or 24.18%, to $14.08 after its earnings and guidance fell well short of expectations. Also lower were shares of Textron (TXT), down $3.94, or 13.42%, to $25.41 after the company reported first quarter results that missed expectations and it cut its full-year view... INDICES: The Dow was down 138.19, or 0.94%, to 14,618.59; the Nasdaq was down 59.96, or 1.84%, to 3,204.67; and the S&P 500 was down 22.56, or 1.43%, to 1,552.01.
News For AAPL;CRUS;BAC;ENDP;ACUR;ALKS;EOPN;TXT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
January 13, 2015
10:59 EDTAAPLApple rises after Credit Suisse, Canaccord hike iPhone estimates
Shares of Apple (AAPL) are climbing after two research firms issued upbeat notes on the company in notes to investors today. WHAT'S NEW: Credit Suisse analyst Kulbinder Garcha upgraded Apple to Outperform from Market Perform. The company should sell 215M iPhones in both fiscal 2015 and fiscal 2016, Garcha estimated. Meanwhile, Apple's gross margins are being boosted by the increased popularity of both its 64 GB memory phones and of the IPhone 6 Plus, the analyst stated. Garcha increased his earnings per share estimate for the iPhone maker by 18% in fiscal 2015 and 20% in fiscal 2016. Additionally, the firm believes excessive net cash levels indicate a new $200B return program should occur. The analyst thinks the shares can reach $130 at least. After analyzing surveys in the U.S. that took place in December and into January, Canaccord analyst T. Michael Walkley said the surveys showed strong demand and market share gains for the new iPhones. The analyst increased his iPhone estimates for Apple's December quarter, as well as his estimates for the company's overall December quarter results. The increases were based on the positive demand trends, particularly for models with higher memory levels and prices, Walkley stated. He expects these positive trends to continue and reiterated a $135 price target and Buy rating on the shares. PRICE ACTION: In mid-morning trading, Apple climbed $3.39, or 3.1%, to $112.64.
10:00 EDTAAPLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:36 EDTAAPLActive equity options trading
Active equity options trading according to Track Data: AAPL AMD AA TWTR GILD C CELG TSLA GOOG
09:07 EDTAAPLOn The Fly: Pre-market Movers
HIGHER: Apple (AAPL), up 1.4% after Credit Suisse upgraded Apple to Outperform and raised its iPhone volume estimates again... Best Buy (BBY), up 2.8% after being upgraded to Buy from Neutral at Goldman... SunPower (SPWR), up 2.6% after being upgraded to Outperform at Credit Suisse... Alcoa (AA), up 2% after Q4 results beat expectations. RISING AFTER GUIDANCE: Pharmacyclics (PCYC), up 17.5%... CTI BioPharma (CTIC), up 8.3%... Emulex (ELX), up 15.5%... ARIAD (ARIA), up 2.6%. LOWER: ChannelAdvisor (ECOM), down 42% following preliminary fourth quarter revenue guidance and after receiving multiple analyst downgrades... Antares Pharma (ATRS), down 7.7% after the FDA recommended that the company create a larger safety database for its clinical development program for QuickShot Testosterone.
07:44 EDTBACNationstar, non-bank lenders could get boost from refis, WSJ says
As a decline in interest rates and a reduction in federal loan fees boosts refinancing activity, smaller banks and non-bank lenders, such as Quicken Loans, loanDepot, and Nationstar Mortgage (NSM), may be in a better position than large banks to benefit, said The Wall Street Journal. Publicly traded large U.S. banks include Bank of America (BAC), Citi (C), JPMorgan (JPM), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
07:42 EDTALKSJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
07:36 EDTAAPLApple survey suggests demand remains strong, says Canaccord
Subscribe for More Information
07:18 EDTAAPLQuanta ramps up production of 12-inch MacBook Air, DigiTimes reports
Subscribe for More Information
07:15 EDTEOPNNeedham to hold a conference
Subscribe for More Information
06:21 EDTAAPLApple upgraded at Credit Suisse
As previously reported, Credit Suisse upgraded Apple to Outperform from Neutral. The firm raised iPhone volume estimates again to 215M units for both FY15/16 and sees $10 EPS power in CY16 based on a solid and sustainable iPhone trends combined with a muted response from Samsung. Additionally, the firm believes excessive net cash levels indicate a new $200B return program should occur. Price target raised to $130 from $110.
06:20 EDTAAPLApple supplier shows 'unbreakable' smartphone with sapphire display, WSJ says
Subscribe for More Information
06:18 EDTAAPLSilicon Valley shuttle drivers looking to unionize, USA Today reports
Subscribe for More Information
06:09 EDTAAPLApple implied volatility of 38 at upper end of index mean range
Subscribe for More Information
06:06 EDTAAPLApple upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
January 12, 2015
16:50 EDTAAPLGartner says worldwide PC shipments in Q4 grew 1%
Subscribe for More Information
16:00 EDTAAPLOptions Update; January 12, 2015
iPath S&P 500 VIX Short-Term Futures up 1.57 to 33.54. Option volume leaders: AAPL TSLA TWTR AMZN AA SIRI RIG FRO C according to Track Data.
12:53 EDTAAPLApple falls, levels to watch
Subscribe for More Information
09:34 EDTAAPLActive equity options trading
Subscribe for More Information
09:17 EDTACURAcura Pharma price target lowered to $1 from $1.50 at Roth Capital
Subscribe for More Information
08:21 EDTAAPLApple poised to gain market share, says JMP Securities
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use